Q-TWiST Analysis of Sacituzumab Govitecan vs. Chemotherapy in Previously Treated Patients with HR+/HER2- Metastatic Breast Cancer

By sjmartinez • March 27, 2025

Rugo HS, Bardia A, Schmid P, Tolaney SM, Dasgupta A, Kaushik A, Verret W, Gosset M, Brufsky A, Cortés J, Marmé F. Q-TWiST Analysis of Sacituzumab Govitecan vs. Chemotherapy in Previously Treated Patients with HR+/HER2- Metastatic Breast Cancer. Curr Oncol. 2025 Mar 15;32(3):169. doi: 10.3390/curroncol32030169. PMID: 40136373; PMCID: PMC11941552.

Tags: antibody-drug conjugate, breast cancer, Hematology/Oncology, HR+/HER2−, Publications, Q-TWiST, Quality of Life, Sacituzumab govitecan

Related Posts

Analyses of adverse events and patient-reported outcomes with the toxicity index in cancer clinical trials

Gresham G, Henry NL, Bandos H, Calsavara VF, Cecchini RS, Diniz MA, Hays RD, Luu M, Kim S, Rogatko A, Yothers G, Ganz PA, Tighiouart[...]

Anti-VEGF neutralizing antibody delays osteomucosal healing by reducing collagen formation in mice

Bae EB, Kim MY, Ji S, Cho IW, Kim SY, Esmaeili M, Baik SS, Kim S, Tetradis S, Park NH, Gwack Y, Kim RH. Anti-VEGF[...]

Collagen-binding IL-12-armoured STEAP1 CAR-T cells reduce toxicity and treat prostate cancer in mouse models

Sasaki K, Bhatia V, Asano Y, Bakhtiari J, Kaur P, Wang C, Matsuo T, Dubois O, Chiu PC, Gun D, Singh C, Panagi I, Noblecourt[...]